| Jul 12 |
MorphoSys declares voluntary delisting from Nasdaq
|
| Jul 12 |
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
|
| Jul 8 |
MorphoSys: Novartis Deal Is All But Done
|
| Jun 20 |
Novartis intends to implement merger squeeze-out of MorphoSys minority shareholders
|
| Jun 20 |
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
|
| Jun 20 |
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
|
| May 23 |
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
|
| May 17 |
Erasca restructures; Novartis moves to complete MorphoSys deal
|
| May 16 |
MorphoSys gains after Novartis discloses all tender offer conditions were met
|
| May 10 |
MorphoSys (ETR:MOR) shareholders have earned a 228% return over the last year
|
